Polymerase inhibitors

Either a DNA or RNA polymerase has been still an important enzyme target for seeking a potent enzyme inhibitor as an antiviral drug until today, despite a huge progress was achieved for the treatment of HIV, HCV, and Coronavirus. These enzymes are usually composed of several domains or units with difference functionalities, for instance, as a helicase for opening the double strand of DNA or RNA molecules, as a nuclease for proof-reading, and function as polymerase activities for nucleic acid chain extension reaction. Therefore, different types of inhibitors can be developed as a non-nucleoside inhibitor or as a chain-terminating inhibitor. The mechanism is different upon non-nucleoside inhibitors which dysfunction of the catalytic site, and nucleoside inhibitors as a chain terminated inhibitor that are covalently incorporated into the growing RNA chain and stop intaking next coming nucleotide triphosphate during RNA chain extension reaction, and lead to completely block the replication of the viral. Efficient and duration efficiency of drug-resistant are completely dependent on the conformation of enzyme target molecules, and the exact conformation of enzyme molecules is always dynamic, so drug-resistant effects of diseases become possible due to the changeable conformation of viral enzymes for non-nucleoside inhibitors or nucleoside-inhibitors in a cellular environment. We are expertise in designing and syntheses of chemical modified nucleoside inhibitors either for RNA dependent RNA polymerases or DNA dependent DNA polymerases.